Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Dec;49(12):967–970. doi: 10.1136/jcp.49.12.967

Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma.

H Hareyama 1, N Sakuragi 1, S Makinoda 1, S Fujimoto 1
PMCID: PMC499642  PMID: 9038731

Abstract

AIMS: To evaluate the clinical usefulness of CA72-4 as a serum tumour marker for endometrial carcinoma and to investigate its immunohistochemical localisation in endometrial carcinoma cells. METHODS: Serum concentrations of CA72-4 were determined in 72 patients with endometrial carcinoma. Immunohistochemical localisation of CA72-4 was investigated using the streptavidin-biotin method, using monoclonal antibodies B72.3 and CC49. RESULTS: Serum CA72-4 was increased above the cut off value in 31.9% of the patients with endometrial carcinoma. Serum CA72-4 positivity was correlated with depth of myometrial invasion, adnexal metastasis, lymphovascular space involvement, and pelvic and para-aortic lymph node metastasis. Multivariate analysis showed a significant correlation between serum CA72-4 positivity and adnexal metastasis. The serum concentrations of CA125 and CA19-9, which could be tumour markers for endometrial carcinoma, were measured at the same time. In seven of 72 patients increased concentrations of serum CA72-4 were found while those for CA125 and CA19-9 were within the normal ranges; in four of the seven patients the disease had spread beyond the uterus. Immunohistochemical positivity for CA72-4 antigen was 76.9% and occurred in the tumour cell membrane and cytoplasm. There was no significant difference in immunohistochemical positivity between patients with increased CA72-4 and those with normal CA72-4 values. CONCLUSIONS: The measurement of serum concentrations of CA 72-4 could be useful for predicting and monitoring the progress of disease-for example, extracorporeal spread.

Full text

PDF
970

Images in this article

969Image
on p.969
969Image
on p.969

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalders J., Abeler V., Kolstad P., Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980 Oct;56(4):419–427. [PubMed] [Google Scholar]
  2. Barss V. A., Benacerraf B. R., Greene M. F., Frigoletto F. D. Use of a small-gauge needle for intrauterine fetal transfusions. Am J Obstet Gynecol. 1986 Nov;155(5):1057–1058. doi: 10.1016/0002-9378(86)90348-0. [DOI] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen S. S., Lee L. Retroperitoneal lymph node metastases in Stage I carcinoma of the endometrium: correlation with risk factors. Gynecol Oncol. 1983 Dec;16(3):319–325. doi: 10.1016/0090-8258(83)90157-9. [DOI] [PubMed] [Google Scholar]
  5. Christopherson W. M., Connelly P. J., Alberhasky R. C. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer. 1983 May 1;51(9):1705–1709. doi: 10.1002/1097-0142(19830501)51:9<1705::aid-cncr2820510924>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Colcher D., Hand P. H., Nuti M., Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A. 1981 May;78(5):3199–3203. doi: 10.1073/pnas.78.5.3199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamazoe R., Maeta M., Matsui T., Shibata S., Shiota S., Kaibara N. CA72-4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer. Eur J Cancer. 1992;28A(8-9):1351–1354. doi: 10.1016/0959-8049(92)90517-6. [DOI] [PubMed] [Google Scholar]
  8. Hanson M. B., van Nagell J. R., Jr, Powell D. E., Donaldson E. S., Gallion H., Merhige M., Pavlik E. J. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 1985 Apr 15;55(8):1753–1757. doi: 10.1002/1097-0142(19850415)55:8<1753::aid-cncr2820550823>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  9. Kato H., Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977 Oct;40(4):1621–1628. doi: 10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  10. Lotocki R. J., Copeland L. J., DePetrillo A. D., Muirhead W. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol. 1983 May 15;146(2):141–145. doi: 10.1016/0002-9378(83)91042-6. [DOI] [PubMed] [Google Scholar]
  11. Negishi Y., Iwabuchi H., Sakunaga H., Sakamoto M., Okabe K., Sato H., Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol. 1993 Feb;48(2):148–154. doi: 10.1006/gyno.1993.1026. [DOI] [PubMed] [Google Scholar]
  12. Negishi Y., Iwabuchi H., Sakunaga H., Sakamoto M., Okabe K., Sato H., Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol. 1993 Feb;48(2):148–154. doi: 10.1006/gyno.1993.1026. [DOI] [PubMed] [Google Scholar]
  13. Niloff J. M., Klug T. L., Schaetzl E., Zurawski V. R., Jr, Knapp R. C., Bast R. C., Jr Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984 Apr 15;148(8):1057–1058. doi: 10.1016/s0002-9378(84)90444-7. [DOI] [PubMed] [Google Scholar]
  14. Paterson A. J., Schlom J., Sears H. F., Bennett J., Colcher D. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int J Cancer. 1986 May 15;37(5):659–666. doi: 10.1002/ijc.2910370504. [DOI] [PubMed] [Google Scholar]
  15. Patsner B., Mann W. J., Cohen H., Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol. 1988 Feb;158(2):399–402. doi: 10.1016/0002-9378(88)90163-9. [DOI] [PubMed] [Google Scholar]
  16. Pittaway D. E., Fayez J. A. Serum CA-125 antigen levels increase during menses. Am J Obstet Gynecol. 1987 Jan;156(1):75–76. doi: 10.1016/0002-9378(87)90207-9. [DOI] [PubMed] [Google Scholar]
  17. Pittaway D. E., Fayez J. A. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril. 1986 Nov;46(5):790–795. doi: 10.1016/s0015-0282(16)49812-2. [DOI] [PubMed] [Google Scholar]
  18. Shitara M., Yoshioka H., Sakurabayashi I., Kawai T., Suzuki M. [Fundamental studies and the reference values of cancer associated antigen TAG-72 (CA72-4)]. Rinsho Byori. 1988 Oct;36(10):1177–1181. [PubMed] [Google Scholar]
  19. Soper J. T., Berchuck A., Olt G. J., Soisson A. P., Clarke-Pearson D. L., Bast R. C., Jr Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1204–1209. doi: 10.1016/0002-9378(90)90692-z. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES